Full text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Alternative delivery systems such as the high-density microarray patch (HD-MAP) are being widely explored due to the variety of benefits they offer over traditional vaccine delivery methods. As vaccines are dry coated onto the HD-MAP, there is a need to ensure the stability of the vaccine in a solid state upon dry down. Other challenges faced are the structural stability during storage as a dried vaccine and during reconstitution upon application into the skin. Using a novel live chimeric virus vaccine candidate, BinJ/DENV2-prME, we explored a panel of pharmaceutical excipients to mitigate vaccine loss during the drying and storage process. This screening identified human serum albumin (HSA) as the lead stabilizing excipient. When bDENV2-coated HD-MAPs were stored at 4 °C for a month, we found complete retention of vaccine potency as assessed by the generation of potent virus-neutralizing antibody responses in mice. We also demonstrated that HD-MAP wear time did not influence vaccine deposition into the skin or the corresponding immunological outcomes. The final candidate formulation with HSA maintained ~100% percentage recovery after 6 months of storage at 4 °C.

Details

Title
Developing a Stabilizing Formulation of a Live Chimeric Dengue Virus Vaccine Dry Coated on a High-Density Microarray Patch
Author
Choo, Jovin J Y 1   VIAFID ORCID Logo  ; McMillan, Christopher L D 1   VIAFID ORCID Logo  ; Fernando, Germain J P 2   VIAFID ORCID Logo  ; Hall, Roy A 1 ; Young, Paul R 1   VIAFID ORCID Logo  ; Hobson-Peters, Jody 1   VIAFID ORCID Logo  ; Muller, David A 2   VIAFID ORCID Logo 

 Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia; [email protected] (J.J.Y.C.); [email protected] (C.L.D.M.); [email protected] (G.J.P.F.); [email protected] (R.A.H.); [email protected] (P.R.Y.); [email protected] (J.H.-P.) 
 Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia; [email protected] (J.J.Y.C.); [email protected] (C.L.D.M.); [email protected] (G.J.P.F.); [email protected] (R.A.H.); [email protected] (P.R.Y.); [email protected] (J.H.-P.); Translational Research Institute, Vaxxas Pty Ltd., 37 Kent Street, Brisbane, QLD 4102, Australia 
First page
1301
Publication year
2021
Publication date
2021
Publisher
MDPI AG
e-ISSN
2076393X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2602201363
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.